ResMed Inc. Reports Fiscal‑Year 2026 Results: Revenue Growth, Margin Expansion, and Dividend Increase
ResMed Inc. released its fiscal‑year 2026 financial results on August 6, 2026, providing a detailed outlook for 2027 and highlighting strategic transactions that shape the company’s future trajectory.
Key Financial Highlights
| Metric | FY 2026 | FY 2025 | Change |
|---|---|---|---|
| Revenue | $3.18 billion | $2.93 billion | +9 % |
| Operating Margin | 22.1 % | 20.9 % | +1.2 pp |
| Earnings Per Share (EPS) | $4.85 | $4.70 | +3.4 % |
| Quarterly Dividend | $0.66 | $0.60 | +10 % |
The company’s operating margin expansion is attributed to a higher proportion of high‑margin sleep‑therapy devices, improved manufacturing efficiencies, and cost‑control initiatives across its global supply chain. EPS growth, while modest, reflects disciplined capital allocation and the incremental contribution of newly launched product lines.
Strategic Business Moves
- Divestiture of MatrixCare Residential‑Care Software
- The sale of MatrixCare, a residential‑care software unit, is anticipated to close in early fiscal 2027.
- Management expects the transaction to provide liquidity that will be redirected toward core sleep‑and‑breathing solutions and digital health initiatives.
- Acquisition of Noctrix Health
- Noctrix Health, a maker of wearable devices for restless‑leg syndrome, was fully acquired in the second quarter of FY 2026.
- The integration of Noctrix’s sensor technology and data analytics platform is projected to broaden ResMed’s portfolio into movement‑related sleep disorders, a market that has demonstrated consistent growth.
- Global Product Expansion
- New device models were launched in Taiwan, the United States, and South America during FY 2026.
- These launches are part of ResMed’s strategy to capture emerging markets where sleep‑disorder prevalence is rising and reimbursement frameworks are becoming more supportive.
Guidance for Fiscal 2027
ResMed’s management provided the following outlook:
| Metric | Guidance |
|---|---|
| Underlying Revenue Growth | 5 %–7 % |
| EPS Growth | 12 %–14 % |
| Capital Return Program | $1.85 billion (share repurchases + dividends) |
| Free Cash Flow | Sufficient to sustain investment in innovation and digital capabilities |
Risk Factors Addressed
Field‑Safety Recall of the Astral Ventilator The recall, initiated to address a firmware issue, has introduced short‑term production delays and regulatory scrutiny. ResMed’s response plan includes expedited firmware updates, enhanced quality‑control procedures, and transparent communication with clinicians.
Competitive Landscape The anticipated re‑entry of Philips into the U.S. market in 2027 poses competitive pressure. ResMed’s focus on differentiated product features, such as advanced data analytics and integrated sleep‑disorder diagnostics, aims to maintain its market share.
Impact of Weight‑Loss Drugs on Demand The widespread adoption of weight‑loss medications has altered long‑term patient profiles, potentially reducing the incidence of certain sleep‑disorder comorbidities. ResMed is monitoring epidemiologic data to adjust its product mix accordingly.
Market Reaction
- NYSE After‑Hours Trading: Shares fell by approximately 6 %.
- ASX Trading: Shares mirrored the U.S. decline.
Analysts emphasize the need to assess how rising component and freight costs could erode margins in the near term. The integration of Noctrix Health and the completion of the MatrixCare divestiture will also be scrutinized for execution risk. However, the company’s robust capital return commitment and the projected free‑cash‑flow base are viewed as positive signs of financial resilience.
Implications for Healthcare Providers and Patients
- Product Availability: The new device models, especially those introduced in South America, will extend access to evidence‑based therapy for obstructive sleep apnea (OSA) and other breathing disorders.
- Digital Health: Integration of Noctrix’s wearable technology will allow clinicians to capture objective movement data, improving diagnostic accuracy for restless‑leg syndrome and potentially reducing reliance on polysomnography.
- Reimbursement: Expanded product portfolios may align with evolving reimbursement codes that favor devices with comprehensive data analytics, potentially improving payer coverage and patient out‑of‑pocket costs.
Conclusion
ResMed’s FY 2026 performance demonstrates sustainable revenue growth and margin improvement, underpinned by strategic divestitures and acquisitions. While the company faces external challenges—such as product recalls and intensified competition—the guidance for FY 2027 reflects confidence in its core sleep‑and‑breathing business and a clear commitment to shareholder value through a sizable capital return program. Healthcare stakeholders should monitor how the company translates its digital initiatives into clinical outcomes, as this will be a key determinant of its competitive positioning in a rapidly evolving therapeutic landscape.
